Vicore Pharma Valuation
| VICO Stock | SEK 23.30 0.30 1.30% |
At this time, the company appears to be overvalued. Vicore Pharma Holding has a current Real Value of kr21.02 per share. The regular price of the company is kr23.3. Our model measures the value of Vicore Pharma Holding from inspecting the company fundamentals such as Shares Outstanding of 81.85 M, price to book of 8.67 X, and Return On Equity of -0.99 as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Vicore Pharma's price fluctuation is not too volatile at this time. Calculation of the real value of Vicore Pharma Holding is based on 3 months time horizon. Increasing Vicore Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Vicore Pharma's intrinsic value may or may not be the same as its current market price of 23.30, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 23.3 | Real 21.02 | Hype 23.3 | Naive 24.86 |
The intrinsic value of Vicore Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Vicore Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Vicore Pharma Holding helps investors to forecast how Vicore stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vicore Pharma more accurately as focusing exclusively on Vicore Pharma's fundamentals will not take into account other important factors: Vicore Pharma Total Value Analysis
Vicore Pharma Holding is at this time estimated to have takeover price of 1.22 B with market capitalization of 1.26 B, debt of 320 K, and cash on hands of 215.97 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Vicore Pharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
| 1.22 B | 1.26 B | 320 K | 215.97 M |
Vicore Pharma Asset Utilization
One of the ways to look at asset utilization of Vicore is to check how much profit was generated for every dollar of assets it reports. Vicore Pharma Holding has a negative utilization of assets of -0.49 %, losing kr0.004902 for each kronor of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each kronor of assets it has. In other words, asset utilization of Vicore Pharma Holding shows how discouraging it operates for each kronor spent on its assets.Vicore Pharma Ownership Allocation
Vicore Pharma maintains a total of 81.85 Million outstanding shares. Over half of Vicore Pharma's outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Vicore Pharma Holding. Please watch out for any change in the institutional holdings of Vicore Pharma as this could mean something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.Vicore Pharma Profitability Analysis
Net Loss for the year was (296.48 M) with profit before overhead, payroll, taxes, and interest of 0.About Vicore Pharma Valuation
The stock valuation mechanism determines the current worth of Vicore Pharma Holding on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Vicore Pharma Holding. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Vicore Pharma Holding based exclusively on its fundamental and basic technical indicators. By analyzing Vicore Pharma's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Vicore Pharma's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Vicore Pharma. We calculate exposure to Vicore Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Vicore Pharma's related companies.Vicore Pharma Holding AB , through its subsidiaries, operates as a biotech company. Vicore Pharma Holding AB was founded in 2000 and is based in Mlndal, Sweden. Vicore Pharma is traded on Stockholm Stock Exchange in Sweden.
8 Steps to conduct Vicore Pharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Vicore Pharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Vicore Pharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Vicore Pharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Vicore Pharma's revenue streams: Identify Vicore Pharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Vicore Pharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Vicore Pharma's growth potential: Evaluate Vicore Pharma's management, business model, and growth potential.
- Determine Vicore Pharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Vicore Pharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Vicore Stock Analysis
When running Vicore Pharma's price analysis, check to measure Vicore Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vicore Pharma is operating at the current time. Most of Vicore Pharma's value examination focuses on studying past and present price action to predict the probability of Vicore Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vicore Pharma's price. Additionally, you may evaluate how the addition of Vicore Pharma to your portfolios can decrease your overall portfolio volatility.